Recovery & Tissue Repair Research Peptides, Arranged on a Timeline

The short version

Restorative Peptides is a reading desk. It is not a shop, not a clinic and not a source of advice. It gathers what the published research says about three research peptides studied for tissue repair: BPC-157, TB-500, and the two-peptide pairing the research-use community calls Wolverine. A peptide is a short chain of amino acids — the same building blocks that make up proteins, only far smaller.

What makes this desk different is the question it asks. Most peptide pages ask whether something works. This one asks how long: how long each study ran, when the first measurable change showed up, and whether the effect was still there when the researchers stopped looking.

That question has an uncomfortable answer. Almost every timeline in this literature was measured in rats. The small number of human studies measured safety over days or weeks — not healing. Nothing on this site recommends a dose, and no interval quoted here should be read as a schedule for a person.

Why this desk reads the record as a clock

Healing is not an event. It is a sequence: bleeding stops, immune cells clear damaged tissue, new matrix and new blood vessels are laid down, and the repaired tissue is then slowly remodelled toward something that can bear load again. Each stage has different cellular work to do, which means a compound that helps at one stage is not automatically doing anything at another.

That staging is not an abstraction imposed from outside. It sits inside the biology of one of the compounds on this desk: thymosin beta-4, the parent protein behind TB-500, is released by platelets and macrophages at the site of an injury, where it is described as limiting apoptosis and inflammation while promoting cell migration and new vessel growth ^[10]. The peptide is, in other words, part of the body's own timed response to damage.

The published research is much less orderly about time than the biology is. A typical repair study reports a single scored endpoint — tendon strength, ulcer area, vessel density — at one moment chosen by the investigators, without saying when the effect began or whether it persisted. Reading these papers as a timeline is therefore partly an exercise in noticing what was never measured. This desk marks those gaps rather than smoothing them over.

The organising frame for the whole site is restoration over time: what repair studies show at each phase of healing — and, just as often, what they show at no phase at all.

What research peptides are

Peptides are short amino-acid chains that act as signals. The three entries on this desk are not approved medicines anywhere; they are sold by suppliers for laboratory research use only, and each carries its own regulatory status, which is stated plainly on its page.

BPC-157 is a 15-amino-acid sequence derived from a fragment of a protein found in human gastric juice. TB-500 is a synthetic seven-amino-acid fragment, Ac-LKKTETQ, corresponding to residues 17 to 23 of the 43-residue protein thymosin beta-4 — the region that binds actin. Wolverine is not a distinct molecule at all but a co-formulated pairing of the other two.

One consequence of that last point runs through the whole site: because 'TB-500' as sold is a fragment while most of the encouraging research used the whole parent protein, any timeline borrowed from the parent protein is a borrowed timeline, not a measured one. The same caution applies twice over to the blend, which inherits it.

Where a number appears on this site — a dose, a duration, a percentage — it is reported exactly as the cited study reported it, together with the species it was measured in. It is never offered as a recommendation.

Three clocks, three species

The three compounds occupy very different positions on the time axis, and the differences are not subtle.

• BPC-157 is the most-studied and the most paradoxical. Its first formal pharmacokinetic characterisation, in rats and beagle dogs, found linear kinetics, an elimination half-life under thirty minutes, intramuscular bioavailability of roughly 14 to 19 per cent in rats and 45 to 51 per cent in dogs, and rapid breakdown into small fragments entering ordinary amino-acid metabolism ^[3]. Its reported repair effects — accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional and microscopic measures ^[6], and a 45.7 to 65.6 per cent reduction in gastric ulcer formation in rats ^[5] — unfold over a far longer span than the molecule itself survives.
• TB-500 carries the one genuinely dated recovery curve in this corpus. In male Wistar rats with embolic middle cerebral artery occlusion, intraperitoneal thymosin beta-4 begun 24 hours after the stroke and repeated every three days improved neurological function significantly from day 14 through day 56 at 2 and 12 mg/kg, while 18 mg/kg produced no significant benefit ^[9].
• Wolverine has no clock of its own. The 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies — 35 preclinical and a single 12-patient retrospective human report — found no clinical safety data, rated the evidence at the lowest tiers, and made no mention of TB-500 or of any combination ^[13].

A side-by-side comparison sets the three clocks against each other, including the species each was measured in.

Where the timeline runs out

It is worth stating the blank spaces early, because they are larger than the record.

No controlled human trial has measured time-to-healing for any compound on this desk. The human evidence that does exist is about tolerability, not repair: an intravenous safety pilot in two adults reported no adverse events and no measurable change in cardiac, hepatic, renal, thyroid or glucose markers ^[1], and a randomised placebo-controlled Phase 1 study gave synthetic thymosin beta-4 intravenously to 40 healthy volunteers in four cohorts of ten, as a single dose and then daily for 14 days, with no dose-limiting toxicities and no serious adverse events ^[11]. Both describe a safety window. Neither describes a healing curve.

A 2025 narrative review of BPC-157 for musculoskeletal healing concluded that despite broad preclinical support, human data remain extremely limited — only three pilot studies — that rigorous large-scale trials are lacking, and that the compound should be treated as investigational ^[2]. A 2026 review of approved and unapproved peptide therapies for musculoskeletal injury reached a similar verdict across the class: favourable tissue-repair outcomes in animal models, scarce human safety data, potential for serious harm, and operation largely outside regulatory oversight ^[8].

The research-use community fills that vacuum with its own timelines — first week, three weeks, six weeks. Those accounts are collected on each compound page and labelled for what they are. They are not measurements.